News
Wegovy, Zepbound and Novo Nordisk
Digest more
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...
People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...
Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.
CVS said Caremark will offer Wegovy at "a more affordable price ... from analysts and investors worried about direct competition in the market between Zepbound and Wegovy. Lilly executives ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...
Caremark negotiated an undisclosed lower ... meaning they can still decide to include Zepbound. Regardless, the CVS-Wegovy deal overshadowed an overall strong quarter for Eli Lilly.
CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback